Bayer CropScience Earmarks Almost $1B in US Investments for 2013 to 2016 | GenomeWeb

NEW YORK (GenomeWeb) – Bayer CropScience today said that it is investing almost $1 billion in capital expenditures in the US between 2013 and 2016 to build up its R&D capabilities and expand its supply of crop protection brands.

The funding is part of a global investment program that Bayer CropScience began last year with total capital expenditures of €2.4 billion ($3.3 billion) between 2013 and 2016.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.